Epigenetics and Cancer: Histone Modifications

Epigenetics in Biology and Medicine

Volumn , Issue , 2008, Pages 17-26

  Fraga, Mario F ^a   Esteller, Manel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72449173064     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (78)

1. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427-5440.
2. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693-705.
3. Turner BM. Cellular memory and the histone code. Cell. 2002;111:285-291.
4. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007;8:286-298.
5. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer. 2004;112:171-178.
6. Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, et al. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol. Rep. 2003;10:333-338.
7. Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int. J. Cancer. 2004;110:362-367.
8. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, et al. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer. 2005;8:86-94.
9. Ono S, Oue N, Kuniyasu H, Suzuki T, Ito R, et al. Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J. Exp. Clin. Cancer Res. 2002;21:377-382.
10. Yasui W, Oue N, Ono S, Mitani Y, Ito R, et al. Histone acetylation and gastrointestinal carcinogenesis. Ann. N.Y. Acad. Sci. 2003;983:220-231.
11. Faure AK, Pivot-Pajot C, Kerjean A, Hazzouri M, Pelletier R, et al. Misregulation of histone acetylation in Sertoli cell-only syndrome and testicular cancer. Mol. Hum. Reprod. 2003;9:757-763.
12. Nouzova M, Holtan N, Oshiro MM, Isett RB, Munoz-Rodriguez JL, et al. Epig-enomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J. Pharmacol. Exp. Ther. 2004;311:968-981.
13. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005;37:391-400.
14. Seligson DB, Horvath S, Shi T, Yu H, Tze S, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262-1266.
15. Kang J, Zhang D, Chen J, Liu Q, Lin C. Antioxidants and trichostatin A synergistically protect against in vitro cytotoxicity of Ni2+ in human hepatoma cells. Toxicol. In Vitro. 2005;19:173-182.
16. Kang J, Zhang D, Chen J, Lin C, Liu Q. Involvement of histone hypoacetylation in Ni2+-induced bcl-2 down-regulation and human hepatoma cell apoptosis. J. Biol. Inorg. Chem. 2004;9:713-723.
17. Kang J, Zhang Y, Chen J, Chen H, Lin C, et al. Nickel-induced histone hypoacetylation: the role of reactive oxygen species. Toxicol. Sci. 2003;74:279-286.
18. Broday L, Peng W, Kuo MH, Salnikow K, Zoroddu M, et al. Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res. 2000;60:238-241.
19. Biron VL, McManus KJ, Hu N, Hendzel MJ, Underhill DA. Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Dev. Biol. 2004;276:337-351.
20. Prokocimer M, Margalit A, Gruenbaum Y. The nuclear lamina and its proposed roles in tumorigenesis: projection on the hematologic malignancies and future targeted therapy. J. Struct. Biol. 2006;155:351-360.
21. Sarg B, Koutzamani E, Helliger W, Rundquist I, Lindner HH. Postsynthetic trimethyl-ation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J. Biol. Chem. 2002;277:39195-39201.
22. Olins DE, Olins AL. Granulocyte heterochromatin: defining the epigenome. BMC Cell Biol. 2005;6:39.
23. Pogribny IP, Ross SA, Tryndyak VP, Pogribna M, Poirier LA, et al. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis. 2006;27:1180-1186.
24. Tryndyak VP, Kovalchuk O, Pogribny IP. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol. Ther. 2006;5:65-70.
25. Tryndyak VP, Muskhelishvili L, Kovalchuk O, Rodriguez-Juarez R, Montgomery B, et al. Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis. 2006;27:1713-1720.
26. Chen YX, Fang JY, Lu R, Qiu DK. Expression of p21(WAF1) is related to acetylation of histone H3 in total chromatin in human colorectal cancer. World J. Gastroenterol. 2007;13:2209-2213.
27. Chen YX, Fang JY, Zhu HY, Lu R, Cheng ZH, et al. Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. World J. Gastroenterol. 2004;10:2643-2646.
28. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074-1080.
29. Herranz M, Esteller M. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets. Methods Mol. Biol. 2007;361:25-62.
30. Ozdag H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genom-ics. 2006;7:90.
31. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 2000;14:1021-1026.
32. Shore D, Squire M, Nasmyth KA. Characterization of two genes required for the position-effect control of yeast mating-type genes. EMBO J. 1984;3:2817-2823.
33. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999;13:2570-2580.
34. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403:795-800.
35. Lin SJ, Kaeberlein M, Andalis AA, Sturtz LA, Defossez PA, et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature. 2002;418:344-348.
36. Chen WY, Wang DH, Yen RC, Luo J, Gu W, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005;123:437-448.
37. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23:2369-2380.
38. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137-148.
39. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149-159.
40. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U.S.A. 2005;102:1859-1864.
41. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, et al. Human SirTl interacts with histone Hl and promotes formation of facultative heterochromatin. Mol. Cell. 2004;16:93-105.
42. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006;2:e40.
43. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116:551-563.
44. Bouras T, Fu M, Sauve AA, Wang F, Quong AA, et al. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J. Biol. Chem. 2005;280:10264-10276.
45. Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J. Cell Physiol. 2006;210:161-166.
46. Wang C, Chen L, Hou X, Li Z, Kabra N, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat. Cell Biol. 2006;8:1025-1031.
47. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305:390-392.
48. Fu M, Liu M, Sauve AA, Jiao X, Zhang X, et al. Hormonal control of androgen receptor function through SIRT1. Mol. Cell Biol. 2006;26:8122-8135.
49. Afshar G, Murnane JP. Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene. 1999;234:161-168.
50. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, et al. Histone deacety-lases in acute myeloid leukemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19:1751-1759.
51. Fraga MF, Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle. 2005;4:1377-1381.
52. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011-2015.
53. Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyl-transferase activity. Biochem. Biophys. Res. Commun. 1999;260:273-279.
54. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell. 2003;11:437-444.
55. Dryden SC, Nahhas FA, Nowak JE, Goustin AS, Tainsky MA. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell Biol. 2003;23:3173-3185.
56. Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 2006;20:1256-1261.
57. Turner BM, Fellows G. Specific antibodies reveal ordered and cell-cycle-related use of histone-H4 acetylation sites in mammalian cells. Eur. J. Biochem. 1989;179:131-139.
58. Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science. 2006;311:844-847.
59. Gupta A, Sharma GG, Young CS, Agarwal M, Smith ER, et al. Involvement of human MOF in ATM function. Mol. Cell Biol. 2005;25:5292-5305.
60. Taipale M, Rea S, Richter K, Vilar A, Lichter P, et al. hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol. Cell Biol. 2005;25:6798-6810.
61. Smith ER, Cayrou C, Huang R, Lane WS, Cote J, et al. A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol. Cell Biol. 2005;25:9175-9188.
62. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem. Biophys. Res. Commun. 2003;309:558-566.
63. Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 2006.
64. Isaac CE, Francis SM, Martens AL, Julian LM, Seifried LA, et al. The retinoblastoma protein regulates pericentric heterochromatin. Mol. Cell. Biol. 2006;26:3659-3671.
65. Siddiqui H, Fox SR, Gunawardena RW, Knudsen ES. Loss of RB compromises specific heterochromatin modifications and modulates HPlalpha dynamics. J. Cell Physiol. 2007;211:131-137.
66. Shumaker DK, Dechat T, Kohlmaier A, Adam SA, Bozovsky MR, et al. Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc. Natl. Acad. Sci. U.S.A. 2006;103:8703-8708.
67. Broers JL, Kuijpers HJ, Ostlund C, Worman HJ, Endert J, et al. Both lamin A and lamin C mutations cause lamina instability as well as loss of internal nuclear lamin organization. Exp. Cell Res. 2005;304:582-592.
68. Cadinanos J, Varela I, Lopez-Otin C, Freije JM. From immature lamin to premature aging: molecular pathways and therapeutic opportunities. Cell Cycle. 2005;4:1732-1735.
69. Espada J, Ballestar E, Fraga MF, Villar-Garea A, Juarranz A, et al. Human DNA meth-yltransferase 1 is required for maintenance of the histone H3 modification pattern. J. Biol. Chem. 2004;279:37175-37184.
70. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006;38:566-569.
71. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006;66:4368-4377.
72. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006;25:176-185.
73. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 2002;277:45099-45107.
74. Avalos JL, Bever KM, Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol. Cell. 2005;17:855-868.
75. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. U.S.A. 2001;98:15113-15118.
76. Olaharski AJ, Rine J, Marshall BL, Babiarz J, Zhang L, et al. The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet. 2005;1:e77.
77. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 2005;48:8045-8054.
78. Golebiowski F, Kasprzak KS. Inhibition of core histones acetylation by carcinogenic nickel(II). Mol. Cell Biochem. 2005;279:133-139.